![](/img/cover-not-exists.png)
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Rudin, Charles M, Pietanza, M Catherine, Bauer, Todd M, Ready, Neal, Morgensztern, Daniel, Glisson, Bonnie S, Byers, Lauren A, Johnson, Melissa L, Burris, Howard A, Robert, Francisco, Han, Tae H, BhedVolume:
18
Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(16)30565-4
Date:
January, 2017
File:
PDF, 300 KB
english, 2017